PURIFIED CORTROPHIN GEL (repository corticotropin) by ANI Pharmaceuticals is unknown. Approved for exacerbations of multiple sclerosis in adults, acute exacerbations of multiple sclerosis in adults, multiple sclerosis and 3 more indications. First approved in 1954.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
Purified Cortrophin Gel is a repository corticotropin (ACTH) injection approved since 1954 for acute exacerbations of multiple sclerosis and rheumatoid arthritis. It stimulates the adrenal cortex to secrete cortisol and other corticosteroids, with additional effects on melanocortin receptors. The exact mechanism of therapeutic benefit in MS and RA remains incompletely understood beyond adrenal stimulation and potential immune modulation.
Product is at peak lifecycle stage with stable market presence, but minimal linked job postings suggest a specialized, smaller commercial footprint managed by ANI Pharmaceuticals.
unknown. Acthar Gel and endogenous ACTH stimulate the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances. Prolonged administration of large doses of Acthar Gel induces hyperplasia and hypertrophy of the adrenal cortex and continuous high…
Adrenocorticotropic Hormone
Worked on PURIFIED CORTROPHIN GEL at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moCortrophin is a niche, specialty product managed by ANI Pharmaceuticals with minimal linked job postings, indicating a small, stable commercial organization focused on maintenance rather than high-velocity growth. Career opportunities are limited to smaller regional teams and specialized neurology/rheumatology field roles rather than corporate-scale commercial or R&D infrastructure.